ASA404
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Cancer With Impaired Renal Function
Conditions
Metastatic Cancer With Impaired Renal Function, Metastatic Cancer With Normal Renal Function
Trial Timeline
Jan 1, 2010 → —
NCT ID
NCT01240642About ASA404
ASA404 is a phase 1 stage product being developed by Novartis for Metastatic Cancer With Impaired Renal Function. The current trial status is terminated. This product is registered under clinical trial identifier NCT01240642. Target conditions include Metastatic Cancer With Impaired Renal Function, Metastatic Cancer With Normal Renal Function.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01240642 | Phase 1 | Terminated |
| NCT01278849 | Phase 1 | Terminated |
| NCT01299701 | Phase 1 | Terminated |
| NCT00674102 | Phase 1 | Completed |
Competing Products
20 competing products in Metastatic Cancer With Impaired Renal Function